Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Cardiac Event Clear all
Terminated Phase 3 Interventional

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT03510897
View directory record Official record
Conditions
Cardiac Surgery
Interventions
teprasiran, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jun 11, 2026, 1:35 AM EDT
Terminated Not applicable Interventional Results available

ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients

NCT01424722
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
97
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jun 11, 2026, 1:35 AM EDT
Completed No phase listed Observational

Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)

NCT02332070
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency
Interventions
cardiac surgery
Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
Not listed
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Jun 11, 2026, 1:35 AM EDT
Recruiting Phase 3 Interventional

Abatacept in Immune Checkpoint Inhibitor Myocarditis

NCT05335928
View directory record Official record
Conditions
Myocarditis Acute, Cancer
Interventions
Abatacept plus, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
29
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jun 11, 2026, 1:35 AM EDT
Withdrawn No phase listed Observational

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

NCT01796743
View directory record Official record
Conditions
Myocardial Infarction, Acute
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Jun 11, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events

NCT01572909
View directory record Official record
Conditions
Reperfusion Injury, STEMI
Interventions
Bendavia (MTP-131), Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Port Orange, Florida • Detroit, Michigan • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jun 11, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events

NCT06048068
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Educational Informational Platform
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 11, 2026, 1:35 AM EDT
Completed Phase 4 Interventional

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

NCT04363697
View directory record Official record
Conditions
Acute Heart Failure, Heart Failure
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The TIMI Study Group
Other
Eligibility
18 Years and older
Enrollment
2,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jun 11, 2026, 1:35 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Jun 11, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

NCT00548587
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
E5555, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Beloit, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jun 11, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 95 Years
Enrollment
4,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jun 11, 2026, 1:35 AM EDT
Not listed No phase listed Observational

Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19

NCT05228717
View directory record Official record
Conditions
Lung Injury, ARDS, Acute Cardiac Event, Covid19, Ultrasound, Hypoxemia, Acute Respiratory Distress Syndrome
Interventions
Point of Care Ultrasound
Diagnostic Test
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Sylmar, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jun 11, 2026, 1:35 AM EDT
Active, not recruiting Phase 3 Interventional

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

NCT05746559
View directory record Official record
Conditions
Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Interventions
Placebo, Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
29
States / cities
Tucson, Arizona • Orange, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 11, 2026, 1:35 AM EDT
Completed No phase listed Observational

Incident COronary EveNts Identified by Computed Tomography

NCT02959099
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Miami, Florida • Bethesda, Maryland • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jun 11, 2026, 1:35 AM EDT
Completed No phase listed Observational

Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events

NCT01436773
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Jun 11, 2026, 1:35 AM EDT
Recruiting Phase 4 Interventional

The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

NCT06802224
View directory record Official record
Conditions
Anesthesia, Surgery With General Anesthesia, Noncardiac Surgery, Hypotension During Surgery, Acute Kidney Injury (AKI), Myocardial Injury After Noncardiac Surgery (MINS), Vasopressor
Interventions
Norepinephrine, Phenylephrine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
San Francisco, California • College Park, Maryland • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 11, 2026, 1:35 AM EDT
Completed No phase listed Observational

ECG Methods for the Prompt Identification of Coronary Events

NCT04237688
View directory record Official record
Conditions
Chest Pain, Myocardial Infarction, Myocardial Ischemia, Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Jun 11, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

NCT00809965
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
Interventions
Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
15,526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Jun 11, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

NCT01000727
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Darapladib 160 mg, Placebo, Standard Therapy
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
13,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
290
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jun 11, 2026, 1:35 AM EDT
Not listed No phase listed Observational

Characterization and Prediction of Atrial Fibrillation-caused Adverse Events After Hospital Discharge for Cardiac Surgery

NCT03466125
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Acute, Death
Interventions
Cardiac surgery
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 99 Years
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 11, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

NCT02145468
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
3,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
91
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Jun 11, 2026, 1:35 AM EDT
Terminated Phase 3 Interventional Results available

Phase III Acute Coronary Syndrome

NCT00831441
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
7,484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Jun 11, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

NCT00552188
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
VIA-2291, Placebo
Drug
Lead sponsor
Tallikut Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Jun 11, 2026, 1:35 AM EDT
Terminated Not applicable Interventional

Positive Emotions After Acute Coronary Events at Northwestern University

NCT04062383
View directory record Official record
Conditions
ACS - Acute Coronary Syndrome
Interventions
Positive Psychology + Motivational Interviewing
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jun 11, 2026, 1:35 AM EDT